Greenwich LifeSciences (GLSI) Competitors $11.09 +0.15 (+1.37%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$10.95 -0.14 (-1.26%) As of 08/1/2025 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GLSI vs. SEPN, ABUS, EOLS, ZVRA, BCYC, KROS, TYRA, RAPP, ARVN, and TSHAShould you be buying Greenwich LifeSciences stock or one of its competitors? The main competitors of Greenwich LifeSciences include Septerna (SEPN), Arbutus Biopharma (ABUS), Evolus (EOLS), Zevra Therapeutics (ZVRA), Bicycle Therapeutics (BCYC), Keros Therapeutics (KROS), Tyra Biosciences (TYRA), Rapport Therapeutics (RAPP), Arvinas (ARVN), and Taysha Gene Therapies (TSHA). These companies are all part of the "pharmaceutical products" industry. Greenwich LifeSciences vs. Its Competitors Septerna Arbutus Biopharma Evolus Zevra Therapeutics Bicycle Therapeutics Keros Therapeutics Tyra Biosciences Rapport Therapeutics Arvinas Taysha Gene Therapies Septerna (NASDAQ:SEPN) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk. Do analysts rate SEPN or GLSI? Septerna presently has a consensus price target of $26.75, suggesting a potential upside of 119.08%. Greenwich LifeSciences has a consensus price target of $39.00, suggesting a potential upside of 251.67%. Given Greenwich LifeSciences' stronger consensus rating and higher possible upside, analysts clearly believe Greenwich LifeSciences is more favorable than Septerna.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Septerna 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Greenwich LifeSciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better valuation & earnings, SEPN or GLSI? Greenwich LifeSciences has lower revenue, but higher earnings than Septerna. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSepterna$1.08M503.78-$71.80MN/AN/AGreenwich LifeSciencesN/AN/A-$15.79M-$1.26-8.80 Does the media refer more to SEPN or GLSI? In the previous week, Septerna had 2 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 2 mentions for Septerna and 0 mentions for Greenwich LifeSciences. Septerna's average media sentiment score of 0.00 equaled Greenwich LifeSciences'average media sentiment score. Company Overall Sentiment Septerna Neutral Greenwich LifeSciences Neutral Is SEPN or GLSI more profitable? Septerna's return on equity of 0.00% beat Greenwich LifeSciences' return on equity.Company Net Margins Return on Equity Return on Assets SepternaN/A N/A N/A Greenwich LifeSciences N/A -450.87%-333.18% Do institutionals and insiders hold more shares of SEPN or GLSI? 4.2% of Greenwich LifeSciences shares are owned by institutional investors. 4.3% of Septerna shares are owned by insiders. Comparatively, 51.7% of Greenwich LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummarySepterna and Greenwich LifeSciences tied by winning 5 of the 10 factors compared between the two stocks. Get Greenwich LifeSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GLSI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GLSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLSI vs. The Competition Export to ExcelMetricGreenwich LifeSciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$146.25M$3.00B$5.47B$9.53BDividend YieldN/A2.44%4.74%4.08%P/E Ratio-8.8017.6228.6723.80Price / SalesN/A269.12422.3188.12Price / CashN/A41.9535.4557.96Price / Book58.378.508.275.55Net Income-$15.79M-$55.06M$3.24B$259.03M7 Day Performance-4.15%-3.98%-3.63%-4.56%1 Month Performance12.25%9.59%4.40%4.49%1 Year Performance-22.77%6.72%25.97%18.05% Greenwich LifeSciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLSIGreenwich LifeSciences1.3032 of 5 stars$11.09+1.4%$39.00+251.7%-28.4%$146.25MN/A-8.803Positive NewsSEPNSepterna1.2235 of 5 stars$13.83-0.4%$26.75+93.4%N/A$618.47M$1.08M0.00N/AABUSArbutus Biopharma2.1633 of 5 stars$3.35+4.0%$5.50+64.2%-14.2%$616.72M$6.17M-8.1790News CoveragePositive NewsUpcoming EarningsEOLSEvolus3.5485 of 5 stars$9.28-2.6%$23.75+155.9%-34.8%$614.45M$266.27M-10.43170News CoverageUpcoming EarningsZVRAZevra Therapeutics2.0705 of 5 stars$10.81-3.7%$23.71+119.4%+76.3%$614.05M$23.61M-5.6920Trending NewsShort Interest ↑Analyst RevisionBCYCBicycle Therapeutics3.4132 of 5 stars$8.61-1.0%$24.22+181.3%-67.2%$602.51M$35.28M-2.74240Positive NewsUpcoming EarningsKROSKeros Therapeutics2.5375 of 5 stars$14.51+0.3%$30.56+110.6%-71.6%$587.29M$214.71M-80.61100News CoverageUpcoming EarningsTYRATyra Biosciences1.6466 of 5 stars$11.11+0.5%$30.83+177.5%-51.8%$587.17MN/A-6.8220News CoverageUpcoming EarningsShort Interest ↑RAPPRapport Therapeutics1.1907 of 5 stars$16.74+4.3%$28.00+67.3%-31.0%$585.79MN/A-4.85N/AARVNArvinas3.4676 of 5 stars$7.61-2.9%$20.29+166.6%-72.3%$572.25M$263.40M-11.53420News CoverageUpcoming EarningsTSHATaysha Gene Therapies2.4132 of 5 stars$2.67+0.8%$8.17+205.9%+21.8%$568.85M$7.22M-7.85180News CoverageShort Interest ↑ Related Companies and Tools Related Companies SEPN Competitors ABUS Competitors EOLS Competitors ZVRA Competitors BCYC Competitors KROS Competitors TYRA Competitors RAPP Competitors ARVN Competitors TSHA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GLSI) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Greenwich LifeSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Greenwich LifeSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
